Currently running trials in advanced non-small Cell Lung Cancer combining the MEK inhibitor MEK162 with the PI3Kα inhibitor BYL719 (NCT02276027) or the MEK inhibitor Selumetinib with mTOR inhibitor AZD2014 (NCT02583542) underscore their therapeutic potential. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.